BRAF and differentiated thyroid carcinoma: While BRAF V600E was selected in this study as a proof-of-concept marker due to its high specificity for papillary thyroid carcinoma, CytoMatrix has the potential to support more comprehensive molecular testing strategies beyond single-gene analysis [20,28,29].